NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, Price Target & More

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) released its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.01. The biopharmaceutical company earned $8.59 million during the quarter, compared to analysts' expectations of $11.18 million. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 773.82%. The company's quarterly revenue was up 776.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.30) earnings per share. View Synergy Pharmaceuticals' Earnings History.

8 brokers have issued 1 year price targets for Synergy Pharmaceuticals' stock. Their predictions range from $2.50 to $15.00. On average, they anticipate Synergy Pharmaceuticals' stock price to reach $8.8125 in the next year. This suggests a possible upside of 363.8% from the stock's current price. View Analyst Ratings for Synergy Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Synergy Pharmaceuticals saw a decline in short interest during the month of June. As of June 29th, there was short interest totalling 54,868,105 shares, a decline of 12.8% from the June 15th total of 62,939,216 shares. Based on an average daily volume of 3,251,186 shares, the days-to-cover ratio is currently 16.9 days. Approximately 22.3% of the company's shares are short sold. View Synergy Pharmaceuticals' Current Options Chain.

Some companies that are related to Synergy Pharmaceuticals include Cambrex (CBM), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Corcept Therapeutics (CORT), IMMURON Ltd/S (IMRN), ARMO Biosciences (ARMO), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), G1 Therapeutics (GTHX), Biohaven Pharmaceutical (BHVN), Deciphera Pharmaceuticals (DCPH), TherapeuticsMD (TXMD) and Mirati Therapeutics (MRTX).

Press coverage about SGYP stock has been trending somewhat negative on Wednesday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a news impact score of -0.15 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.56 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SGYP stock can currently be purchased for approximately $1.90.

Synergy Pharmaceuticals has a market capitalization of $466.34 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]